TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1744422

Group type: EXPERIMENTAL
Intervention: 2 mg of molsidomine (n = 11)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 4 mg of molsidomine (n = 8)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 27
Study: 7145537

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apneas
Number of subjects: 75

Group type: COMPARATOR
Intervention: Central sleep apneas
Number of subjects: 75
Study: 31626819

Group type: EXPERIMENTAL
Intervention: Omegaven (Ω3‐FAs)
Number of subjects: 261
Study: 31544382

Group type: EXPERIMENTAL
Intervention: Eye acupuncture combined with conventional acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medication (sodium hyaluronate eye drops)
Number of subjects: 90
Study: 29237679

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg once daily)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 25331981

Group type: EXPERIMENTAL
Intervention: Self-administered parent training with minimal therapist contact (written material and brief weekly telephone consultations)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-administered parent training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waitlist control group (WLC)
Number of subjects: 48
Study: 23928735

Group type: EXPERIMENTAL
Intervention: ICE + EAM
Number of subjects: 84

Group type: COMPARATOR
Intervention: EAM only
Number of subjects: 84
Study: 22119521

Group type: COMPARATOR
Intervention: Assessment condition
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Readiness to change
Number of subjects: 299
Study: 20969665

Group type: EXPERIMENTAL
Intervention: LGP‐HA+L (large-gel particle hyaluronic acid plus 0.3% lidocaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LGP‐HA (large-gel particle hyaluronic acid without lidocaine)
Number of subjects: 60
Study: 17939882

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Gatifloxacin 0.3%
Number of subjects: 59
Study: 16370302

Group type: EXPERIMENTAL
Intervention: Bilateral laminotomy (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Unilateral laminotomy (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laminectomy (Group 3)
Number of subjects: 120
Study: 11955728

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day (20 milliliters po qAM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) for head-and-neck cancer patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) for lung cancer patients
Number of subjects: 56
Study: 9536950

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for one week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 15
Study: 7642012

Group type: EXPERIMENTAL
Intervention: Flecainide (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sotalol (Group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Flecainide and Sotalol
Number of subjects: 66
Study: 1695785

Group type: EXPERIMENTAL
Intervention: Alpha blockers (e.g., prazosin, terazosin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonselective alpha blockers (e.g., phenoxybenzamine)
Number of subjects: 0
Study: 29806

Group type: EXPERIMENTAL
Intervention: Methylergonovine maleate (MEM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no MEM)
Number of subjects: 200
Study: 30654912

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation of 4000 IU daily for three years
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 27564599

Group type: EXPERIMENTAL
Intervention: 200 IU onabotulinum toxin A (onaBoNT‐A)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 24723058

Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Number of subjects: 25
Study: 21983916

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waiting-list (control)
Number of subjects: 35
Study: 22105592

Group type: EXPERIMENTAL
Intervention: Metformin exposure with contrast media (CM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ClCr before CM exposure
Number of subjects: 50

Group type: COMPARATOR
Intervention: ClCr after CM exposure
Number of subjects: 50
Study: 18334122

Group type: EXPERIMENTAL
Intervention: Thyroidectomy and ipsilateral central lymph node dissection (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Thyroidectomy (Group B)
Number of subjects: 84
Study: 16365066

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (50 mg/d)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (fruit cereal bars without soy isoflavones)
Number of subjects: 89
Study: 12801622

Group type: EXPERIMENTAL
Intervention: xuezhikang 1200 mg/day (600 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine therapy (control group)
Number of subjects: 50
Study: 10950032

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 338

Group type: COMPARATOR
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 338

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 338
Study: 8836825

Group type: EXPERIMENTAL
Intervention: Experimental group (smoking cessation intervention)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 349
Study: 1565785

Group type: EXPERIMENTAL
Intervention: Solid bolus
Number of subjects: 104

Group type: COMPARATOR
Intervention: Liquid bolus
Number of subjects: 104
Study: 2865275

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (2.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Midazolam (0.07 mg/kg IV bolus, maintained by 0.025 to 0.04 mg/kg/hr infusion for eight hours)
Number of subjects: 6
Study: 28282996

Group type: EXPERIMENTAL
Intervention: Skills training
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Skills training with peer-led support
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Skills training with peer support
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 137
Study: 29649248

Group type: COMPARATOR
Intervention: Non-orphaned children
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Orphaned children
Number of subjects: 370
Study: 27157027

Group type: EXPERIMENTAL
Intervention: Motivational text message intervention adjunct to cognitive-behavioral therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Motivational text message intervention
Number of subjects: 12
Study: 24830223

Group type: EXPERIMENTAL
Intervention: Interactive educational session
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Recall
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both strategies together
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 22503201

Group type: EXPERIMENTAL
Intervention: Antegrade cerebral perfusion (ACP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 25
Study: 20231242

Group type: EXPERIMENTAL
Intervention: Full-item WISDM (68-item version)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced-item WISDM (37-item version)
Number of subjects: 0
Study: 18310553

Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control (after receiving TAP)
Number of subjects: 60
Study: 15925286

Group type: EXPERIMENTAL
Intervention: Impact (Japan) supplement (1 L/d for 5 days before surgery)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Impact (Japan) supplement
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ordinary diet (control group)
Number of subjects: 26
Study: 15521326

Group type: EXPERIMENTAL
Intervention: Novel controlled-release formulations of niacin based on polyethylene oxide (PEO) and hydroxypropylmethyl cellulose (HPMC) matrices.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPMC-based matrix system.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation of interest (specific formulation not detailed).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial product (control).
Number of subjects: 0
Study: 11526359

Group type: EXPERIMENTAL
Intervention: Photopheresis (5 treatments)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Balloon PTCA only / Stents (Control)
Number of subjects: 78
Study: 9232448

Group type: EXPERIMENTAL
Intervention: Birch allergen immunotherapy (IT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8453021

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aerosolized nitroglycerin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sublingual and aerosolized nitroglycerin
Number of subjects: 19
Study: 3310341

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 168
Study: 31179792

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3010

Group type: COMPARATOR
Intervention: BMI >25
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Metabolic syndrome
Number of subjects: 3010

Group type: COMPARATOR
Intervention: PASI score
Number of subjects: 3010
Study: 29527709

Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 758
Study: 27247336

Group type: EXPERIMENTAL
Intervention: Prasugrel or ticagrelor
Number of subjects: 203

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 203
Study: 24430319

Group type: COMPARATOR
Intervention: CEA only (n=300)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: CT only (n=299)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: CEA+CT (n=302)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Minimum follow-up (n=301)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Combined intensive monitoring groups (CEA, CT, CEA+CT)
Number of subjects: 1202
Study: 21519851

Group type: EXPERIMENTAL
Intervention: RTE targeted biopsy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Random biopsy
Number of subjects: 139
Study: 20537815

Group type: EXPERIMENTAL
Intervention: Employment (Drug or Money)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Punishment (Drug Only+Money Loss)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Unemployment (Drug Only)
Number of subjects: 11
Study: 18950299

Group type: EXPERIMENTAL
Intervention: ICD implantation in patients with valvular cardiomyopathy
Number of subjects: 17

Group type: COMPARATOR
Intervention: ICD implantation in patients with ischemic cardiomyopathy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ICD implantation in both groups
Number of subjects: 17
Study: 16497309

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14606736

Group type: EXPERIMENTAL
Intervention: Musical motor feedback (MMF) therapy, 15 sessions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional gait therapy, 15 sessions
Number of subjects: 23
Study: 11105402

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional classroom lecture (TCL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CAI and TCL
Number of subjects: 0
Study: 8872686

Group type: EXPERIMENTAL
Intervention: Propofol 0.125 mg/kg injection, propofol 12.5 mcg/kg/min infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol 0.25 mg/kg injection, propofol 25 mcg/kg/min infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg injection, propofol 50 mcg/kg/min infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fentanyl 1.4 mcg/kg injection (positive control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline, Intralipid)
Number of subjects: 12
Study: 1326277

Group type: EXPERIMENTAL
Intervention: High-dose marihuana (2.53% delta 9-tetrahydrocannabinol)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo marihuana
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-dose marihuana (1.26% delta 9-tetrahydrocannabinol)
Number of subjects: 15
Study: 3880992

Group type: EXPERIMENTAL
Intervention: Digoxin (0.50 mg intravenously in 20 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo saline solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 40
Study: 31746877

Group type: EXPERIMENTAL
Intervention: Blueberry (BB) supplementation (1 cup per day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Strawberry (SB) supplementation (2 cups per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100
Study: 29289658

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26781620

Group type: EXPERIMENTAL
Intervention: Cascade (n=25)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 6-month waitlist (n=22)
Number of subjects: 47
Study: 25368995

Group type: EXPERIMENTAL
Intervention: High vibration group (HVG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low vibration group (LVG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 22974804

Group type: EXPERIMENTAL
Intervention: losmapimod 7.5 mg once daily (lower dose)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: losmapimod 7.5 mg twice daily (higher dose)
Number of subjects: 99
Study: 19890632

Group type: EXPERIMENTAL
Intervention: Recombinant poxviral vaccine with GM-CSF
Number of subjects: 32

Group type: COMPARATOR
Intervention: Recombinant poxviral vaccine without GM-CSF
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Recombinant poxviral vaccine
Number of subjects: 32
Study: 17917313

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for 3 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: No CPAP treatment (control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Patients with AHI >or=20/h
Number of subjects: 51
Study: 15388511

Group type: EXPERIMENTAL
Intervention: infliximab 5 mg/kg every 6 weeks
Number of subjects: 52
Study: 11826333

Group type: EXPERIMENTAL
Intervention: Cochrane review
Number of subjects: 0

Group type: COMPARATOR
Intervention: Narrative review (author and journal concealed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Narrative review (author and journal identified)
Number of subjects: 0
Study: 10442958

Group type: EXPERIMENTAL
Intervention: High dose propofol (2-2.5 mg x kg(‐1) bolus then 200 microg x kg(‐1) x min(‐1))
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low dose propofol (1-2.5 mg x kg(‐1) bolus then 100 microg x kg(‐1) x min(‐1))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isoflurane (0-2%)
Number of subjects: 21
Study: 7771914

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.1 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.3 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.5 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 34
Study: 2182939

Group type: EXPERIMENTAL
Intervention: Sympathetic neurone blockade with debrisoquine for 4 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 375787

Group type: EXPERIMENTAL
Intervention: SHRZ/HRZ regimen (6 months)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: SHRZ/HRZ regimen (4 months)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: SHRZ/HR regimen (6 months)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: SHRZ/HR regimen (4 months)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Patients with bacilli resistant to isoniazid or streptomycin
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 330
Study: 31699210

Group type: EXPERIMENTAL
Intervention: Active lighting intervention
Number of subjects: 46
Study: 28228427

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine
Number of subjects: 11648

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11648
Study: 25867906

Group type: EXPERIMENTAL
Intervention: Electronic sepsis evaluation and management tool (218 patients)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Usual care (189 patients)
Number of subjects: 407
Study: 24129463

Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 1880

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1880
Study: 21415050

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg plus methotrexate (MTX)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg plus methotrexate (MTX)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 619
Study: 19561422

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (Sub/MF59)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Nonadjuvanted split vaccine (split)
Number of subjects: 269
Study: 17339550

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels
Number of subjects: 31546

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels (adjusted for age, sex, smoking, previous myocardial infarction, hypertension, waist‐to‐hip ratio, creatinine, DM, and use of aspirin, beta‐blockers, or statins)
Number of subjects: 31546
Study: 15230816

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily for 1 month, 200 microg twice daily for 5 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) 10 mg three-times daily for 6 months
Number of subjects: 60
Study: 11520335

Group type: EXPERIMENTAL
Intervention: Training with curved lines
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Training with straight lines
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Initial evaluation test
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Final evaluation test after 2nd training session
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 69
Study: 10625576

Group type: EXPERIMENTAL
Intervention: CVI patients with skin lesions during suprasystolic occlusion
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CVI patients with open venous ulcers
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 53
Study: 8904524

Group type: EXPERIMENTAL
Intervention: Palm oil diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betapol diet
Number of subjects: 60
Study: 1864315

Group type: EXPERIMENTAL
Intervention: 600 mg of mifepristone (RU 486)
Number of subjects: 50
Study: 6638543

Group type: EXPERIMENTAL
Intervention: Midazolam-N2O-O2 anesthesia
Number of subjects: 17

Group type: COMPARATOR
Intervention: Thiopental-N2O-O2 anesthesia
Number of subjects: 17
Study: 30566755

Group type: EXPERIMENTAL
Intervention: Enriched Number Talk condition
Number of subjects: 47

Group type: COMPARATOR
Intervention: Counting condition
Number of subjects: 47
Study: 30007091

Group type: EXPERIMENTAL
Intervention: Contraceptive use during latest intercourse
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Intention to have children/more children
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Non-use of contraceptives among women not intending to have children
Number of subjects: 1946
Study: 26038847

Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24887185

Group type: EXPERIMENTAL
Intervention: Linum usitatissimum L. (linseed) oil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22113368

Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TMG)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study: 20599139

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 17324009

Group type: EXPERIMENTAL
Intervention: Plerixafor plus G-CSF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plerixafor as a single mobilising agent
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plerixafor in combination with G-CSF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plerixafor in combination with chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: G-CSF therapy alone
Number of subjects: 50
Study: 16182156

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 390

Group type: COMPARATOR
Intervention: Codeine/acetaminophen 600/60 mg
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 11935151

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors (specifically enalapril, n = 8)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (non-diabetic patients and patients without proliferative diabetic retinopathy, n = 8)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors (enalapril, n = 8)
Number of subjects: 39
Study: 10420105

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 43

Group type: COMPARATOR
Intervention: Halothane/thiopental anesthesia
Number of subjects: 43